BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 5, 2007
View Archived Issues
Potent antiarthritic activity of the MetAP2 inhibitor PPI-2458 shown in a rat RA model
Read More
KV to acquire U.S. marketing rights to EvaMist
Read More
Rhophylac approved for ITP
Read More
IND submission for phase Ia study of intravenous Tbeta4 for cardiovascular disease
Read More
Milestone in Ranbaxy's collaboration with GSK
Read More
Vivitrol filed for approval in U.K. and Germany
Read More
Second pivotal trial begins for naproxcinod
Read More
BTG updates pipeline progress of last year
Read More
Beyond Advair compounds show similar bronchodilator activity to salmeterol
Read More
ACUITY trial shows efficacy at 1 year of bivalirudin in acute coronary syndromes
Read More
Snapshots: Recent studies of antibacterial agents
Read More
BOL-303224-A: a novel fluoroquinolone with potential utility in bacterial conjunctivitis
Read More
Lilly's dual endothelial and hepatic lipase inhibitors modulate HDL cholesterol levels in vivo
Read More
New Nav1.7 channel blocker described by Merck
Read More
Recent patent reports novel therapeutic agents for thrombotic disorders
Read More
Novel agents for treating respiratory and allergic disorders disclosed in recent patents
Read More
Recent patents describe new antidiabetic agents
Read More
CSL submits BLA for influenza vaccine
Read More
Apricitabine shows broader range of activity against drug-resistant HIV strains
Read More
New phase I trial evaluates s.c. Belerofon
Read More
SPA for new phase III trial of Prestara
Read More
Pharmexa and Affitech enter diabody license agreement
Read More
Phase III registration studies of Vectibix not affected by PACCE discontinuation
Read More
Start of pivotal trial for Pollinex Quattro ragweed
Read More
ChemGenex raises funds to support Ceflatonin development program
Read More
NB-002 studied in phase II trial for onychomycosis
Read More
Pharmacyclics' NDA for Xcytrin to be filed over protest
Read More
Supplemental BLA for Campath for first-line treatment of B-CLL
Read More
